
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid Ltd is a clinical-stage biopharmaceutical company advancing its proprietary PLEX technology for targeted drug delivery, focusing on conditions such as surgical site infections with its lead candidate D-PLEX100. Recent developments, including a successful regulatory inspection and a lower-than-expected net loss per share attributed to an increase in share count, bolster investor confidence in the approval prospects for D-PLEX100. Additionally, a strategic collaboration with AdvanzPharma in the EU and the anticipation of a positive outcome from the upcoming pre-NDA meeting highlight the company's potential for significant progress in the biopharmaceutical market.
Bears say
PolyPid faces significant risks surrounding the efficacy of its clinical candidates, as any failure to demonstrate statistically significant results in trials could greatly diminish the value of its product portfolio. Additionally, even successful clinical outcomes do not guarantee regulatory approval from domestic or international authorities, further jeopardizing the company's financial standing. The potential for revenue erosion starting in 2036, stemming from complex patent processes, adds another layer of financial uncertainty for PolyPid’s future performance.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares